Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
ASSETS
Cash and cash equivalents	$ 12,747	$ 24,647
Marketable securities	75,772	70,323
Prepaid and other current assets	2,181	1,212
Total current assets	90,700	96,182
Property and equipment, net	55	62
Other assets	708	764
Total assets	91,463	97,008
Liabilities
Accounts payable	697	1,934
Accrued liabilities	2,104	2,589
Total current liabilities	2,801	4,523
Other long-term liabilities	421	485
Total liabilities	3,222	5,008
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2022 and December 31, 2021, respectively	0	0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 60,544,144 and 59,800,792 shares at March 31, 2022 and December 31, 2021, respectively; and outstanding, 60,533,064 and 59,789,712 shares at March 31, 2022 and December 31, 2021, respectively	61	60
Additional paid-in capital	546,580	545,988
Treasury stock, at cost; 11,080 shares at March 31, 2022 and December 31, 2021	(708)	(708)
Accumulated deficit	(457,242)	(453,016)
Accumulated other comprehensive loss	(196)	(70)
Total Caladrius Biosciences, Inc. stockholders' equity	88,495	92,254
Non-controlling interests	(254)	(254)
Total stockholders' equity	88,241	92,000
Liabilities and Equity, Total	$ 91,463	$ 97,008